Neuropace Inc — Cash Flow (NASDAQ:NPCE) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 24.6 M36.9 M19.7 M17.9 M 16.2 M Cash from investing activities 85.4 M23.8 M23.03 M8.99 M 2.2 M Cash from financing activities 102.53 M490 K8.13 M4.33 M 19.81 M Free cash flow 24.22 M36.3 M19.53 M17.59 M 15.93 M

Noticias

LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates

Leerink Partners eleva el objetivo de precio de las acciones de NeuroPace a 20 dólares desde 19 dólares

Leerink Partners eleva precio objetivo de NeuroPace a $20 desde $19

NeuroPace stock price target raised to $20 from $19 at Leerink Partners

H.C. Wainwright eleva precio objetivo de NeuroPace a $19 desde $18

Objetivo de precio de NeuroPace elevado a 19 dólares desde 18 dólares por H.C. Wainwright

NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Acciones de NeuroPace suben tras reiteración de compra por UBS tras sólidos ingresos